Press Releases

03/12/2019

Menarini Silicon Biosystems Develops New Assay Workflow for Circulating Multiple Myeloma Cells

Technology to Be Introduced at the Molecular Medicine Tri-Conference May Offer Alternative to Invasive Bone Marrow Biopsy for Monitoring Disease Progression

continue →

Topics: FFPE, deparray, CELLSEARCH, Liquid biopsy, Precision Medicine, Multiple myeloma, CMMCs

05/16/2017

Top International Experts Gather to Understand the Many Faces of Cancer

Second World Summit on Cancer Heterogeneity and Precision Medicine Meets in Washington

continue →

Topics: FFPE, CTCs, Liquid biopsy, International experts, Menarini International Foundation, Precision Medicine, Cancer Heterogeneity, International conference

10/25/2016

Menarini-Silicon Biosystems and Swift Biosciences Announce Collaboration to Offer Customized NGS Technologies for Tumor Cell Analysis

Products Optimized for Targeted Resequencing and Exome Sequencing of FFPE Cells

continue →

Topics: FFPE, NGS, target sequencing, exome sequencing

07/1/2015

Silicon Biosystems DEPArray™ technology offers a revolutionary approach to understanding complex cancer genomics in FFPE samples.

Silicon Biosystems, a Bologna (Italy) and San Diego (CA, USA) based biotech company that is part of the pharmaceutical Menarini Group, presented recent findings obtained with its breakthrough state-of-the-art DEPArray™ technology in the characterization of pure tumor cell subpopulations derived from formalin fixed paraffin embedded (FFPE) tissue samples at the European Association of Cancer Research Meeting in Florence (June 20-23).

DEPArray™ technology resolves heterogeneity in solid tumors by digitally sorting 100% pure subpopulations of cells from FFPE samples, thus allowing differential analysis and characterization of tumor vs stromal cell populations resulting in unprecedented data in the subsequent Next Generation Sequencing (NGS) analysis. 

 

 FULL RELEASE

continue →

Topics: FFPE

Ask Us a QuestionShare your DEPArray™ storySubscribe to newsletter